By: Matthew Fischer
With the rapid growth of the regenerative medicine field, the U.S. Food and Drug Administration (FDA) is trying to strike the right balance between preventing harm to the public and fostering innovation of new treatments. In an effort to prevent potential harm, the FDA stepped up enforcement this week. In two complaints filed by the U.S. Department of Justice (DOJ) on behalf of the FDA, the FDA has sought permanent injunctions against a California and Florida stem cell clinic along with their owners and officers to prevent the marketing of stem cell products without FDA approval and for failure to correct deviations from manufacturing practice requirements.
The injunctions are aimed at U.S. Stem Cell Clinic, LLC of Sunrise, Florida and California Stem Cell Treatment Center, Inc. with multiple locations in California. Both companies previously received warning letters from the FDA for administering processed adipose tissue (stromal vascular fraction) to patients to treat a variety of conditions ranging from mascular degeneration to Parkinson’s disease. The letters also addressed the results of inspections and the need to resolve significant deviations from manufacturing practice requirements.
A complaint has been filed for an injunction…now what? Once a complaint for injunction is filed, an injunction may be entered at any time either following a hearing or as a result of a negotiated settlement. If a hearing is held, the burden will be on the government to prove each element required to obtain an injunction by a preponderance of the evidence. As the word “permanent” infers, an injunction will remain in place until removed by an order from the court.
On April 16th, Iowa Senator Chuck Grassley sent a letter to the leadership of the FDA pressing for answers on the results of their investigation into U.S. Stem Cell Clinic, LLC and asked whether the company or any of its employees were referred for potential prosecution. Given the timing of these complaints in relation to Grassley’s letter, are these isolated events in response to the letter or a sign of more enforcement action to come?
The post FDA Stem Cell Clinic Legal Issues: Stepped Up Enforcement appeared first on Florida Healthcare Law Firm.